ELVNEnliven Therapeutics Inc

As the market enters the final stretch of trading, one story is dominating virtually every trading desk on Wall Street: the historic debut of SpaceX. The company's long-awaited public offering has generated extraordinary volume, massive investor interest, and renewed enthusiasm across multiple high-growth sectors including space infrastructure, artificial intelligence, biotechnology, and advanced communications. $NTHI, $SPCX, $ELVN, $POET, $RNAC, $ALOY

As of March 2026, ELVN-001 produced meaningful responses in heavily pretreated patients, many of whom had already tried multiple existing therapies, Enliven Therapeutics said.

Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants PR Newswire BURLINGAME, Calif., June 11, 2026 BURLINGAME, Calif., June 11, 2026...

Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants PR Newswire BURLINGAME, Calif., June 11, 2026 BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven...

Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components PR Newswire BURLINGAME, Calif...

Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress PR Newswire BURLINGAME, Calif...

Key PointsChief Medical Officer Helen Collins sold 5,000 shares of Common Stock for a total of ~$199,000 on May 18, 2026, at an average price of around $39.79 per share...

Enliven Therapeutics to Present at Upcoming Investor Conferences Enliven Therapeutics to Present at Upcoming Investor Conferences PR Newswire BOULDER, Colo., May 21, 2026 BOULDER, Colo., May 21, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a...

Enliven said that updated positive early-stage data for its lead candidate ELVN-001 will be featured in an oral presentation at the EHA 2026 Congress in Stockholm.